Back

Identification of genetic variants in Pfs25 and functional evaluation in mosquito infection

Orfano, A.; Cisse, A.; Guo, Y.; Han, L.; Fikadu, N.; Thiam, L. G.; Ba, A.; Li, R.; Pouye, M. N.; Mangou, K.; Moore, A. J.; Sene, S. D.; Diallo, F.; Ngom, E. M.; Sadio, B.; Mbengue, A.; Membi, C.; Ngasala, B.; Bazie, T.; Some, F. A.; Olson, N.; Patel, S. D.; Shapiro, L.; Parikh, S.; Foy, B. D.; Cappello, M.; Vigan-Womas, I.; Premji, Z.; Dabire, R. K.; Ouedraogo, J.-B.; Sheng, Z.; Bei, A. K.

2026-08-31 infectious diseases
10.64898/2026.08.25.26361130 medRxiv
Show abstract

Transmission-blocking vaccines (TBVs) are a promising strategy to reduce malaria transmission by targeting parasite stages within the mosquito. However, parasite genetic diversity may limit vaccine efficacy. We used next-generation amplicon deep sequencing to identify non-synonymous single nucleotide polymorphisms (SNPs) in Pfs25 from 184 Plasmodium falciparum isolates from Senegal, Tanzania, Ghana, and Burkina Faso. Prioritized SNPs were introduced into P. falciparum via CRISPR-Cas9. For the G116C variant, gametocyte development was evaluated by microscopy and qPCR, and mosquito infectivity was assessed by SMFAs. We identified 26 SNPs, including 24 novel variants. Functional assays showed that the Pfs25 G116C mutation did not affect gametocyte development or exflagellation. SMFA showed no significant differences in oocyst prevalence or intensity between mutant and WT parasites. These findings highlight the importance of integrating genetic surveillance with functional validation to guide the development of effective transmission blocking interventions

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.